Please login to the form below

Not currently logged in
Email:
Password:

bapineuzumab

This page shows the latest bapineuzumab news and features for those working in and with pharma, biotech and healthcare.

Another Alzheimer's bust as Merck & Co stops verubecestat study

Another Alzheimer's bust as Merck & Co stops verubecestat study

BACE inhibitors are designed to block the formation of the amyloid plaques that characterise the disease, unlike earlier antibody drugs such as Lilly’s solanezumab and Pfizer’s bapineuzumab which attempted

Latest news

More from news
Approximately 3 fully matching, plus 33 partially matching documents found.

Latest Intelligence

  • Interview: Mike Hutton, Lilly Interview: Mike Hutton, Lilly

    Work on Pfizer, J&J and Elan's bapineuzumab, Lundbeck/Myriad Genetics' Flurizan, Pfizer and Medivation's Dimebon (latrepirdine), to name a few, has come to a halt in recent years.

  • Interview: Cesar Rodriguez, Janssen Interview: Cesar Rodriguez, Janssen

    And despite recent disappointments involving Alzheimer's candidate bapineuzumab, the company is still committed to tackling the “ huge unmet medical need” of the condition, according to Rodriguez. “

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics